

Centessa takes a step towards a new haemophilia mechanism



[Madeleine Armstrong](#)

Haemophilia gene therapy developers look out. New competition could be on the horizon from Centessa Pharmaceuticals' novel project SerpinPC, which today yielded [promising phase 2 results](#). There are reasons for caution: the dataset was small, comprising just 22 patients, with no placebo control. But an 88% reduction in all bleeds with the highest dose, 1.2mg/kg, at 12 weeks versus baseline got investors' attention, pushing Centessa shares up 16% this morning. The group hopes that SerpinPC could become a one-size-fits-all therapy, regardless of haemophilia type, severity or inhibitor status. Centessa now needs to prove the once-monthly project's benefit in larger registrational studies, but did not give many details during a conference call today. Thrombotic events will also be closely watched given SerpinPC's mechanism. The project is an activated protein C inhibitor designed to restore levels of prothrombinase - this in turn generates thrombin, which is needed for blood clotting. On this point, Centessa execs said they were encouraged by unchanged levels of D-dimer, a marker of excess thrombin. Even if SerpinPC succeeds it will have a hard time catching Roche's approved haemophilia A therapy Hemlibra, which is forecast to sell around \$5bn by 2026, according to *Evaluate Pharma* sellside consensus.

The top-five haemophilia products in 2026

| Product/project | Company | Mechanism | Disease subtype | 2026e sales (\$m) |
|-------------------------------------|--------------|------------------------------------|-------------------|-------------------|
| Hemlibra | Roche/Chugai | Anti-factor IXa & X bispecific MAb | Haemophilia A | 5,590 |
| NovoSeven | Novo Nordisk | Recombinant Factor VII | Haemophilia A & B | 796 |
| Valoctocogene roxaparvovec (valrox) | Biomarin | AAV5 factor VIII gene therapy | Haemophilia A | 695 |
| Kogenate | Bayer | Recombinant Factor VIII | Haemophilia A | 663 |
| Idelvion | CSL | Factor IX-albumin fusion protein | Haemophilia B | 661 |

Source: *Evaluate Pharma*.

[More from Evaluate Vantage](#)

Evaluate HQ
[44-\(0\)20-7377-0800](#)

Evaluate Americas
[+1-617-573-9450](#)

Evaluate APAC
[+81-\(0\)80-1164-4754](#)

© Copyright 2022 Evaluate Ltd.